Factors contributing to the racial differences in prostate cancer mortality

BJU International

Volumn 96, Issue 9, 2005, Pages 1247-1252

  Tewari, Ashutosh ^a   Horninger, Wolfgang ^b   Pelzer, Alexandre E ^b   Demers, Raymond ^a   Crawford, E David ^c   Gamito, Eduard J ^c   Divine, George ^a   Johnson, Christine Cole ^a   Bartsch, George ^b   Menon, Mani ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

African Americans; Mortality; Predictive modelling; Prostate cancer

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; AWARENESS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DEMOGRAPHY; EUROPEAN AMERICAN; HUMAN; KAPLAN MEIER METHOD; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; RACE DIFFERENCE; RISK FACTOR; SOCIOECONOMICS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION;

AFRICAN AMERICANS; AGED; CAUSE OF DEATH; EPIDEMIOLOGIC METHODS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 28544449556     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05824.x     Document Type: Article

References (9)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47
2. Young RC. Cancer statistics, 2002: progress or cause for concern? CA Cancer J Clin 2002; 52: 6-7
3. Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 1998; 36: 1337-48
4. Sohayda CJ, Kupelian PA, Altsman KA, Klein EA. Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol 1999; 162: 1331-6
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987; 40: 373-83
6. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80
7. Fowler JE Jr, Terrell FL, Renfroe DL Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996; 156: 1714-8
8. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341: 1198-205
9. Edwards QT, Johnson CG, Mason S, Boyle G. Differentiation of the health behavior patterns related to prostate cancer screening among African-American men in military settings. Mil Med 2002; 167: 374-8